Science & Technology
Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41CA291231-01A1
Award Ceiling
$400K
Award Floor
$400K
Close Date
Jul 31, 2025
Total Funding
$400K
Expected Awards
1
Posted Date
Aug 15, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41CA291231-01A1
Description
STTR Phase Phase I award: "Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic" awarded to Sieyax, LLC in BROOMFIELD, Colorado. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $399,709. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.